# Rolvedon

NDC: 76961-101
Generic name: eflapegrastim-xnst
Labeler / Manufacturer: Spectrum Pharmaceuticals, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20221018
Marketing ended: 20270831
FDA application: BLA761148

## Active ingredients

- EFLAPEGRASTIM: 13.2 mg/.6mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"76961-101"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=76961-101
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e436115-62e7-4729-aeb0-ff78ea685206